Evidence map›Paper›PMID 36636121›Full record

ArticleJournal of chemistry2022

Nonhistone Lysine Methylation as a Protein Degradation Signal.

Nicholas A Lehning, Brad E Morrison

Open access · goldAbstract read
In one paragraph

Article in Journal of chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicholas A LehningBiomolecular Ph.D. Program, Boise State University, Boise 83725, ID, USA.
Brad E MorrisonBiomolecular Ph.D. Program, Boise State University, Boise 83725, ID, USA.
Boise State University · US

Funding

Women's health: interplay of maternal diet and key demographics on neurological health in the rural frontier and remote WestP20GM103408 · NIGMS · UNIVERSITY OF IDAHO · PI Carolyn Hovde Bohach · 2012 to 2026
$59.8M
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signalingP20GM109095 · NIGMS · BOISE STATE UNIVERSITY · PI OXFORD, JULIA THOM · 2014 to 2023
$22.7M
Autophagy dysfunction in Parkinson's Disease by VPS35 D620NR15NS096702 · NINDS · BOISE STATE UNIVERSITY · PI MORRISON, BRAD · 2016 to 2017
$521k
NIGMS NIH HHS P20 GM103408NIGMS NIH HHS P20 GM109095NINDS NIH HHS R15 NS096702
6 · The paper itself

Abstract

Protein degradation is a fundamental feature of cellular life, and malfunction of this process is implicated in human disease. Ubiquitin tagging is the best characterized mechanism of targeting a protein for degradation; however, there are a growing number of distinct mechanisms which have also been identified that carry out this essential function. For example, covalent tagging of proteins with sequestosome-1 targets them for selective autophagy. Degradation signals are not exclusively polypeptides such as ubiquitin, NEDD8, and sequestosome-1. Phosphorylation, acetylation, and methylation are small covalent additions that can also direct protein degradation. The diversity of substrate sequences and overlap with other pleotrophic functions for these smaller signaling moieties has made their characterization more challenging. However, these small signals might be responsible for orchestrating a large portion of the protein degradation activity in the cell. As such, there has been increasing interest in lysine methylation and associated lysine methyltransferases (KMTs), beyond canonical histone protein modification, in mediating protein degradation in a variety of contexts. This review focuses on the current evidence for lysine methylation as a protein degradation signal with a detailed discussion of the class of enzymes responsible for this phenomenon.

Identifiers

PMID36636121
PMCPMC9833375
OpenAlexW4221107270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.